Kelly Roberts, PA
Physician Assistant · Las Vegas, NVNPI 1699382465
Payments from drug & device makers
Across 108 payments — averaging $36.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$1K
- Novo Nordisk$776
- Tandem Diabetes Care, Inc.$256
- Abbott$244
- Averitas Pharma Inc.$140
- Insulet Corporation$131
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,955100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 23 | $1,162 |
| Novo Nordisk | 24 | $776 |
| Tandem Diabetes Care, Inc. | 3 | $256 |
| Abbott | 12 | $244 |
| Averitas Pharma Inc. | 3 | $140 |
| Insulet Corporation | 2 | $131 |
| BETA Bionics, Inc. | 1 | $131 |
| Astellas Pharma US Inc | 1 | $124 |
| Bayer | 1 | $95 |
| Amgen | 5 | $87 |
| Lilly USA, LLC | 3 | $83 |
| Xeris Pharmaceuticals, Inc. | 1 | $70 |
| UCB, Inc. | 3 | $69 |
| Ascensia Diabetes Care US Inc. | 1 | $67 |
| Kyowa Kirin, Inc. | 2 | $56 |
| Lifescan, Inc. | 4 | $55 |
| Boehringer Ingelheim | 3 | $52 |
| Soleno Therapeutics, Inc. | 2 | $48 |
| AbbVie | 2 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Madrigal Pharmaceuticals | 1 | $42 |
| Ionis Pharmaceuticals, Inc. | 1 | $29 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| AstraZeneca | 1 | $22 |
| Antares Pharma, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
| Mannkind Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$480
- iLet Bionic Pancreas$394
- Veozah$124
- Wegovy$121
- Ozempic$120
- Qutenza$119
- RYBELSUS$114
- t:slim X2 Insulin Pump with Control-IQ$101
How this compares
$3,955 in reported general payments places this provider in the 85th percentile of 881 physician assistant providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Soliqua 100-33Insulin Glargine/Lixisenatide | 621 | $665,436 |
| OzempicSemaglutide | 320 | $410,433 |
| JardianceEmpagliflozin | 322 | $358,194 |
| MounjaroTirzepatide | 193 | $258,399 |
| TrulicityDulaglutide | 105 | $156,432 |
| Tresiba Flextouch U-100Insulin Degludec | 87 | $94,636 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 493 | $85,310 |
| FarxigaDapagliflozin Propanediol | 69 | $84,081 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 31 | $73,499 |
| Humalog Kwikpen U-100Insulin Lispro | 240 | $65,296 |
| RybelsusSemaglutide | 33 | $64,915 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $56,965 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 57 | $55,052 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $54,908 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $54,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $44 | $671,390653 claims |
| Novo NordiskOzempic, Rybelsus | $776 | $475,348353 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30, Insulin Lispro | $83 | $437,471388 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $52 | $367,015334 claims |
| AstraZenecaFarxiga | $22 | $84,08169 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 881 physician assistant providers in Nevada.
Other physician assistant in Las Vegas
- Steven HawkesLas Vegas$70K
- Nathan MorganLas Vegas$44K
- Stephanie DastrupLas Vegas$23K
- Sandra OviedoLas Vegas$21K
- Patrick JamesonLas Vegas$20K
- Jordan ChristensenLas Vegas$19K
- Jacquelyn DaneshforouzLas Vegas$18K
- Violet AmirjalaliLas Vegas$15K
- Joseph GuruleLas Vegas$15K
- Rebecca Markin-NewsomeLas Vegas$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.